Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAMP-1: Imatinib in LAM
NCT03131999Phase 2Completed
- Sponsor
- Medical University of South Carolina
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lymphangioleiomyomatosis (LAM) comparing Imatinib Mesylate with Placebo (2 arms). Primary endpoint: Log Transformed Serum VEGF-D Level. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT03131999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131999.